Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
NCT ID: NCT07222280
Last Updated: 2025-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2025-06-10
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting?
* Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies
NCT04699786
Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease
NCT02409030
Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay
NCT07099001
Clinical Evaluation of Blood-Based Assays for Rapid Detection of Aβ Pathology in Alzheimer's Disease
NCT06889896
APOE in the Predisposition to, Protection From, and Prevention of Alzheimer's Disease
NCT04994847
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All eligible patients will receive a Quest AD-Detect blood test
All patients that meet the inclusion criteria, and none of the exclusion criteria, will have their blood tested with the Quest AD-Detect
Quest AD-Detect blood test
Blood will be collected and sent for testing using the Quest AD-Detect blood test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quest AD-Detect blood test
Blood will be collected and sent for testing using the Quest AD-Detect blood test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No prior diagnosis of dementia
* Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state
Exclusion Criteria
* Prior diagnosis of dementing illness or other organic etiology to cognitive impairment
60 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Covenant Health, US
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samuel Moore, MD
Role: PRINCIPAL_INVESTIGATOR
Covenant Health, Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cumberland Medical Center
Crossville, Tennessee, United States
Roane Medical Center
Harriman, Tennessee, United States
Fort Sanders Regional Medical Center
Knoxville, Tennessee, United States
Fort Loudon Medical Center
Lenoir City, Tennessee, United States
Methodist Medical Center
Oak Ridge, Tennessee, United States
LeConte Medical Center
Sevierville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADUE2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.